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Abstract
Background: There is a lack of information about the sensitivity, specificity and costs new diagnostic tests should
have to improve early diagnosis of rheumatoid arthritis (RA). Our objective was to explore the early cost-effectiveness
of various new diagnostic test strategies in the workup of patients with inflammatory arthritis (IA) at risk of having RA.
Methods: A decision tree followed by a patient-level state transition model, using data from published literature,
cohorts and trials, was used to evaluate diagnostic test strategies. Alternative tests were assessed as add-on to or
replacement of the ACR/EULAR 2010 RA classification criteria for all patients and for intermediate-risk patients. Tests
included B-cell gene expression (sensitivity 0.60, specificity 0.90, costs €150), MRI (sensitivity 0.90, specificity 0.60, costs
€756), IL-6 serum level (sensitivity 0.70, specificity 0.53, costs €50) and genetic assay (sensitivity 0.40, specificity 0.85,
costs €750). Patients with IA at risk of RA were followed for 5 years using a societal perspective. Guideline treatment
was assumed using tight controlled treatment based on DAS28; if patients had a DAS28 >3.2 at 12 months or later
patients could be eligible for starting biological drugs. The outcome was expressed in incremental cost-effectiveness
ratios (€2014 per quality-adjusted life year (QALY) gained) and headroom.
Results: The B-cell test was the least expensive strategy when used as an add-on and as replacement in
intermediate-risk patients, making it the dominant strategy, as it has better health outcomes and lower costs. As
add-on for all patients, the B-cell test was also the most cost-effective test strategy. When using a willingness-to-pay
threshold of €20,000 per QALY gained, the IL-6 and MRI strategies were not cost-effective, except as replacement.
A genetic assay was not cost-effective in any strategy. Probabilistic sensitivity analysis revealed that the B-cell test was
consistently superior in all strategies. When performing univariate sensitivity analysis for intermediate-risk patients,
specificity and DAS28 in the B-cell add-on strategy, and DAS28 and sensitivity in the MRI add-on strategy had the
largest impact on the cost-effectiveness.
Conclusions: This early cost-effectiveness analysis indicated that new tests to diagnose RA are most likely to be
cost-effective when the tests are used as an add-on in intermediate-risk patients, and have high specificity, and the test
costs should not be higher than €200–€300.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory
joint disease characterised by structural irreversible joint
damage, leading to severe disability, serious loss of qual-
ity of life and premature death if left untreated [1–6].
Disease progression can be slowed down by synthetic
and biologic disease-modifying antirheumatic drugs
(DMARDs), especially if started early in the disease [7–11].
This requires early detection of RA. However, early diagno-
sis is complex, because RA-related symptoms early in the
disease course resemble those of other musculoskeletal dis-
orders [12]. Early detection would result in DMARDs be-
ing started early and improved prognosis. Therefore,
several diagnostic tests are currently being developed to
improve the early diagnosis of RA in patients with inflam-
matory arthritis (IA), e.g., B-cell related gene expression,
IL-6 serum level test, magnetic resonance imaging (MRI)
of hands and feet, and genetic assays with susceptibility
single nucleotide polymorphisms (SNPs) for RA. However,
little is known about their potential cost-effectiveness.
To guide implementation of new diagnostic tests in
the workup of patients at risk of having RA, a decision
model could be used to evaluate the test performance
(i.e., sensitivity and specificity), test costs, and position-
ing of the test in terms of the clinical outcomes and so-
cietal costs. Evaluating the cost-effectiveness of new
drugs before entering the market is well-implemented
because reimbursement authorities request this. How-
ever, it is less common to evaluate the cost-effectiveness
of new medical tests that enter the market while this
also affects healthcare spending directly. Given the
constraints on healthcare budgets, it is likely that
clinicians evaluate the impact of new tests on their de-
partmental budget and consider diagnostic uncertainty.
To inform this clinical decision problem, we conducted
an early cost-effectiveness analysis (early-CEA). In this
analysis, the incremental costs of the new potential and
current diagnostic test strategies are weighed against the
gain in quality-adjusted life years (QALYs) and potential
improved labour force participation [13]. The main
assumption is that early diagnosis results in a timely
start of effective treatment that reduces disease activity
and consequently postpones or prevents treatment with
a biologic DMARD.
The aim of this study was twofold. The first objective
was to develop an early-CEA model to evaluate the costs
and health effects (in terms of QALYs) of new and
current diagnostic test strategies from a societal perspective
in patients with IA who are suspected of having RA. The
second objective was to analyse the costs and health effects
of new test strategies compared to the American College of
Rheumatology/European League Against Rheumatism
(ACR/EULAR) 2010 RA classification criteria (referred to
as RA-2010 criteria).
Methods
We applied the framework following the general steps used
in early-CEA of medical tests as developed by Buisman et
al. [14]. This framework is a useful guidance for researchers
performing early-CEA of medical tests. Early-CEA evalu-
ates medical tests in development by assessing how much
these tests could improve health outcomes and healthcare
efficiency. Moreover, early-CEA helps test developers to
decide about further development of medical tests, set real-
istic performance-price goals and design and manage reim-
bursement strategies [14, 15].
Current diagnostic test strategy
IA patients at risk of having RA undergo a diagnostic
workup to establish the presence of RA. This entails
affected joint counts, blood testing, and radiographs
ordered or established by the rheumatologist. If no other
explanation for the symptoms is found (e.g., systemic
lupus erythematosus (SLE), gout, or psoriatic arthritis)
the patient is classified as having RA if at least 6 out of
10 points on the RA-2010 criteria are scored. Patients
who score less than 6 but more than 2 points are
regarded as patients at intermediate risk who do not ful-
fil the RA-2010 criteria. The RA-2010 criteria were the
comparator in our early-CEA [6].
New diagnostic test strategies
The cost-effectiveness was assessed of four diagnostic
tests that are currently being developed as part of the
TRACER project [16]: B-cell related gene expression
[17], IL-6 serum level test [18], MRI of the hands and
feet [19–24] and genetic assays with susceptibility SNPs
for RA [25]. For each of the tests (described subse-
quently), three different test strategies were modelled:
add-on to the RA-2010 criteria for all patients with IA,
add-on for intermediate-risk patients only and replace-
ment of all blood tests and radiographs used to classify
patients according to the RA-2010 criteria. For the
add-on test strategies, the performance of the new
test strategy was estimated by combining the sensitivity
and specificity of the RA-2010 criteria and the new tests.
B-cell related gene expression
During the development of arthritis, B-cell RNA expres-
sion decreases over time [16]. Although the exact
mechanism is poorly understood, the marker is useful to
predict early arthritis in patients with seropositive arth-
ralgia [17]. Currently no data are available for patients
with IA. Therefore, we used the data from the seroposi-
tive arthralgia cohort studied by Baarsen et al. [17]. After
discussion with the developers of this test, sensitivity of
0.60 and specificity of 0.90 was used. The cost of the test
was set at €150.
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IL-6 serum level test
IL-6 is a cytokine that is present in inflammation. In a
recent evaluation of IL-6 serum level test performance
in detecting RA in patients with IA the sensitivity was
0.70 and specificity was 0.53 [18]. We used these sensi-
tivity and specificity values and assumed a cost of €50
per test.
MRI of hands and feet
MRI may reclassify patients to different joint domains of
the RA-2010 criteria if there are more swollen joints
than are identified on physical examination. MRI also
provides additional information on bone marrow edema
[19] and tenosynovitis [20, 21]. Based on the literature
[22–24] and discussions with test developers, we set the
sensitivity of MRI at 0.90 and the specificity at 0.60. The
costs of MRI were assumed to be equal to the unit costs
currently used by the Dutch Healthcare Authority, of
€189 per MRI examination (€756 for four MRI scans
(both hands and both feet)) [26].
Genetic assay with susceptibility SNPs for RA
RA is a complex disease involving several genes. Herit-
ability for RA is estimated to be around 50–60 % [25].
Expert review of the literature suggests that using gen-
etic risk factors combined with current knowledge would
result in sensitivity of 0.40 and specificity between 0.80
and 0.90 to identify patients with RA [25]. We used
these estimations and applied sensitivity of 0.40 and spe-
cificity of 0.85 with an estimated cost of €750 per test
based on expert opinion from test developers.
Treatment
In the current and new diagnostic test strategies, test-
positive patients received methotrexate (MTX) at
25 mg/week orally [27]. Due to the side effects of MTX,
patients could switch to other synthetic DMARDs (e.g.,
Sulfasalazine, Leflunomide). After failure of two syn-
thetic DMARDs, patients could switch to biologic
DMARDs (i.e., TNF-inhibitors, IL6-inhibitors, B cell de-
pletion, or T cell inhibition) [28].
RA patients who were additionally detected by the
new diagnostic test strategies as compared to the RA-
2010 criteria were assumed to be given early treatment.
As a result, we modelled that they had an improvement
of 0.2 in the disease activity score in 28 joints (DAS28)
at 12 months as compared to patients in the current test
strategy. The improvement of 0.2 in the DAS28 was
based on sensitivity analysis in which we evaluated the
effect of changing this value on the model results (see
univariate sensitivity analysis below).
Model structure
In RA, the diagnosis and subsequent prognosis are com-
plex processes in which various tests and measures of
disease activity influence treatment decisions and subse-
quently outcomes in terms of both costs and effects. As
the diagnosis is often reconsidered in the first year of
disease, especially in those initially not classified as hav-
ing RA, we decided to model the first year as a decision
tree with chance nodes at 6 and 12 months to classify
patients as true positive (TP), false positive (FP), true
negative (TN) and false negative (FN) during the first
year. Patients were classified as TP if they had a positive
test result (≥6 points on the RA-2010 criteria or positive
on the new test) at baseline and at 12 months, used
MTX or stopped MTX due to side effects. Moreover, the
symptoms should not be explained by another classified
diagnosis [6]. Patients were considered as TN if they had
a negative test result (<6 points on the RA-2010 criteria
or negative on the new test) at baseline, did not use
MTX at 12 months, and had symptoms explained by an-
other classified diagnosis. Patients were considered FP if
they scored ≥6 points on the RA-2010 criteria or were
positive on the new test at baseline but did not use
MTX at 12 months, and had symptoms explained by an-
other classified diagnosis. Patients were classified as FN
if they scored <6 points on the RA-2010 criteria or were
negative on the new test at baseline but used MTX or
stopped MTX due to side effects at 12 months, and had
no symptoms explained by another classified diagnosis.
Using a combination of initial RA-2010 criteria scores
and the use of DMARDs not explained by any other dis-
ease is a common way of dealing with a disease for
which no hallmark sign is available [6, 29].
The first year is followed by a four-year individual-
level Markov model (i.e., patient-level state transition
model) that simulates the change in disease activity
(DAS28) over time in 3-month cycles. The cycle time is
3 months because patients are commonly seen by the
rheumatologists every 3 months. This 5-year model was
used to simulate what would happen if a proportion of
FN patients in the current strategy were diagnosed earl-
ier with lower levels of disease activity in the new test
strategy. The time horizon was 5 years because the long-
term effects of biological drug use are unknown. Patients
were categorised into three disease states: remission
(DAS28 ≤ 2.6), low disease activity (DAS28 > 2.6 to ≤3.2)
and moderate and severe disease activity (DAS28 > 3.2).1
This categorization by DAS28 score is common in the
field of RA [30–32]. Resource use, costs and utilities
were linked to these three categories. The patients who
were classified as TP or FN at 12 months entered the
patient-level state transition model. A proportion of pa-
tients with DAS28 > 3.2 were modelled to start a biologic
DMARD in addition to MTX. They were assumed to
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stay on a biologic DMARD and could switch to another
biologic DMARD for the remainder of the 4 years. The
patients who were classified as TN or FP at 12 months
entered a background model in which they stayed for
the remaining 4 years, assuming no change in utilities,
biologic DMARD costs for 10 % of FP patients in the
first year after diagnosis and otherwise, no RA-related
costs. Figure 1 shows the decision model comparing the
current diagnostic test strategy with the new add-on
diagnostic test strategy for intermediate-risk patients
(described subsequently). This 5-year cost-effectiveness
model is an extension of our 1-year model published
elsewhere [33].
Data sources
To populate the model, we mainly used data from three
different sources. Additional file 1: Table S1 shows the
characteristics of the three sources. First, data from the
REACH cohort (usual care) were used to populate the
1-year decision tree with 552 patients with IA who were
suspected of having RA (details about the cohort can be
found in Additional file 2: Table S2). Patients had to
have at least one joint clinically diagnosed as affected by
synovitis that could not be classified as another inflam-
matory joint disease. The prevalence of RA was 54 % at
12 months based on the RA-2010 criteria and MTX use.
Second, data from the tREACH trial were used in our
model for RA patients after 1-year follow-up [34]. The
tREACH trial includes patients aged 18 year-old or older
with arthritis in at least one joint, and symptom duration
less than 1 year. Patients were randomized into three
initial treatment strategies: triple DMARD therapy
(MTX, sulfasalazine and hydroxychloroquine) with intra-
muscular glucocorticoids, triple DMARD therapy with
an oral glucocorticoid tapering scheme and MTX mono-
therapy with an oral glucocorticoid tapering scheme. See
Claessen et al. [35] for a detailed description of the
tREACH trial.
Third, summary data from the DREAM registry as
published by Vermeer et al. [36] were used to inform on
the start of biological drugs. This publication describes
data from two cohorts, a treat-to-target cohort and a
usual-care cohort of patients with clinical RA. The treat-
to-target strategy used a standardized treatment step-up
protocol [36]. In contrast, the treatment switches were
not performed by protocols in the usual care cohort.
Model inputs
Additional file 3: Table S3 gives an overview of all model
input parameters, their estimates and distributions for
probabilistic sensitivity analysis, and data sources.
Estimation of transition probabilities
During the first 12 months of our model, the probabil-
ities of patients being TP, FN, TN and FP were elicited
from the REACH cohort in which patients were classi-
fied according to the RA-2010 criteria, use of MTX and
use of other synthetic DMARDs at baseline, 6 and
12 months.
At the start of the patient-level state transition model
(i.e., at 12 months), the DAS28 of TP and FN patients at
12 months in the REACH cohort resulted in patients
entering one of the three disease states. Patients who
entered the DAS28 >3.2 state at the start or later in time
could be eligible for starting biological drugs. To model
this, summary data from the DREAM cohort on the
start of biological drugs were used, in which the ob-
served use of biologic DMARDs in clinical practice was
Fig. 1 a Decision tree for the first year comparing the current diagnostic test strategy with the new diagnostic add-on test strategy for
intermediate-risk patients. Current test strategy American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010
rheumatoid arthritis (RA) classification criteria. New test strategy add-on test for intermediate-risk patients (3–5 points) according to the ACR/EULAR
2010 RA classification criteria. IA inflammatory arthritis, MTX methotrexate, TP true positive, FP false positive, TN true negative, FN false negative, T0
baseline, T6 6 months, T12 12 months. b Patient-level transition state model and background model of second to fifth year for all test strategies.
DAS28 disease activity score in 28 joints
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15 % at 24 months. We transformed this 15 % rate into
a 3-month transition probability of 2 % to start biologic
DMARDs in those patients with a DAS28 >3.2. This 2 %
was distributed over the three disease states in a 1–3–6
distribution (state 1– state 2– state3) based on flare rates
(DAS28 > 3.2) in the tREACH cohort.
Estimates of resource use and costs
We distinguished two cost categories: direct medical and
productivity costs. Direct medical costs include costs of
visits to rheumatologists and other health professionals
(e.g., physical therapist), laboratory tests including diag-
nostic tests and those to monitor side effects, and medi-
cation use. Productivity costs represent the number of
days that a patient with a paid job was absent from work
in the past 3 months. Resource use and productivity
losses per disease state were obtained from the REACH
study in the first year [29] and from the tREACH study
[34, 35] in the second and third year. The latter was
extrapolated to 5 years. In the background model TN
patients were assumed to incur no RA-related costs,
while 10 % of FP patients incurred biologic DMARD
costs in the first year after diagnosis due to misdiagnosis,
for which the frequency was based on the REACH study.
The unit costs of visits and productivity losses were
based on reference prices published in the Dutch Manual
of Costing in economic evaluations [37]. Diagnostic test
costs were based on tariffs published by the Dutch Health-
care Authority [26], and medication costs were obtained
from the National Health Care Institute [38]. All costs
were adjusted to €2014 using the general price index from
the Dutch Central Bureau of Statistics [39]. All cost pa-
rameters can be found in Additional file 3: Table S3.
Estimation of QALYs
When assessing the impact of a new test or treatment
on quality of life over time, the health outcomes are
usually measured in terms of quality-adjusted life years
(QALYs). The QALY combines the number of life years
with the level of health-related quality of life (i.e.,
utilities) in those years [40]. The EuroQol 5-dimension
3-level questionnaire (EQ-5D-3L) was used to estimate
utilities. The baseline utilities of TP, FP, TN, and FN
were obtained from the REACH study and were 0.60,
0.65, 0.65 and 0.60, respectively. Based on the literature
we assigned an improvement of 0.10 over the first year
to the TPs [41–45]. Based on the REACH study we
assigned an improvement of 0.05 and 0.10 over the first
year to the FPs and TNs, respectively. Based on the pla-
cebo group in the STIVEA trial, we assigned a 0.05 re-
duction over the first year for FNs, assuming that FN
patients would receive little therapy [45].
In the patient-level state transition model, patients
were assigned EQ-5D values based on their DAS28 every
3 months, stratified for the start of biologic DMARDs.
As observed in the tREACH study, the EQ-5D values for
patients not using biologic DMARDs were higher. Fur-
thermore, the EQ-5D values were not normally distrib-
uted. About 25 % of patients in the tREACH study had a
decrease in EQ-5D at least once in 3 years, which led to
a utility score lower than 0.50. Therefore, different distri-
butions of utility values were estimated. One distribution
was estimated for patients with at least one EQ-5D de-
crease below 0.50 over time and another distribution
was estimated for patients who always had an EQ-5D
higher than 0.50 over time. In the background model,
patients were assumed to have an EQ-5D value of 0.75
that remained constant over time.
Analyses/modelling
We performed a base-case analysis with four diagnostic
tests that were used in three diagnostic test strategies as
described above. We calculated the incremental costs
per QALY gained in each new test strategy compared
with the current test strategy (i.e., incremental cost-
effectiveness ratio (ICER)). Probabilistic sensitivity ana-
lyses were performed in which incremental costs and
QALYs were calculated as the mean of 1,000 Monte
Carlo simulations, where each simulation samples simul-
taneously from the appropriate distributions of the input
parameters (see Additional file 3: Table S3 for the distribu-
tions). Cost-effectiveness planes and acceptability curves
were constructed from the Monte Carlo simulation. In
addition, we used the headroom (i.e., potential profit)
method to assess the maximum additional cost for which
each new diagnostic test was still likely to be cost-effective
at a willingness-to-pay threshold of €20,000 per QALY
gained [46, 47].
Furthermore, we explored the impact of our model
parameters in univariate sensitivity analyses, varying the
sensitivity, specificity, new test costs, improvement in
the DAS28 in TP patients in the new test strategy, who
were FN in the current test strategy, and costs of biologic
DMARDs for FP patients in the first year after diagnosis.
The range over which the model parameters were varied
are shown between brackets in Fig. 4. We report these
analyses for an add-on test for intermediate-risk patients.
For each analysis, one model parameter was altered while
the other parameters were held constant at the baseline
value. In our analyses, differential discounting was applied
in accordance with the Dutch guidelines for economic
evaluation research, with an annual discount rate of 4.0 %
for all costs and 1.5 % for health effects [48].
Model validation
The model structure and input parameters were checked
for clinical correctness by rheumatologists. We also verified
the model for coding and logical correctness by running
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extreme value scenarios. Furthermore, an independent
modeller internally validated our model to check the model
structure, all input parameters with distributions and the
visual basic code used to programme the model in Excel.
Ethical approval and patient consent
No ethical approval and consent from patients was
needed for this study.
Results
Reclassification
In the add-on test strategy, only intermediate-risk pa-
tients could be reclassified as high risk or low risk of
having RA, and low-risk patients could be reclassified as
high-risk patients. Table 1 shows the reclassification for
both add-on strategies. Due to the high specificity of the
B-cell test and genetic assay, more patients were reclas-
sified as low risk, while due to the high sensitivity of IL-
6 and MRI, more patients were reclassified as high risk.
Cost-effectiveness
Table 2 shows the results of the RA-2010 criteria and
the four new tests used as add-on for all patients, add-
on for intermediate-risk patients, and replacement of the
RA-2010 criteria.
The B-cell test was the least expensive strategy when
used as an add-on in intermediate-risk patients and as a
replacement test, making it the dominant strategy, as it
has better health outcomes and lower costs. The B-cell
test was also the most cost-effective test strategy as an
add-on in all patients. When using a willingness-to-pay
threshold of €20,000 per QALY gained, the IL-6 and
MRI test strategies were not cost-effective, except in the
replacement strategy. A genetic assay was not cost-
effective in any strategy. When comparing the test strat-
egies, replacement of the RA-2010 criteria was the most
cost-effective test strategy, followed by the add-on test
in intermediate-risk patients, and the least favourable
was the add-on test in all patients.
Headroom
Table 2 shows the maximum additional cost for which
each new test was likely to be cost-effective at a
willingness-to-pay threshold of €20,000 per QALY
gained (i.e., the headroom). Given the sensitivity and
specificity of the different tests, an IL-6 test will only be
cost-effective with a unit cost below €59 in the replace-
ment test strategy. The headroom of a genetic assay test
(€210 as the add-on in all patients, €173 as the add-on in
intermediate-risk patients, and €543 as the replacement)
also shows that the current unit costs of this test were too
high, because the headroom was lower than the current
unit costs of this test (€750).
Probabilistic sensitivity analysis
Figure 2 shows the cost-effectiveness planes with the
average costs and effects and the uncertainty around this
average for the add-on test strategy in intermediate-risk
patients. All estimates lie within the northeast or southeast
quadrants, meaning improved health outcomes. In the
northeast quadrant, this is accompanied by higher costs as
seen for IL-6, MRI, and gene assay. Nearly 100 % of these
estimates (99.6 %, 99.7 %, and 99.8 %, respectively) lie
within this quadrant. For the B cell test, part of the esti-
mate (57.2 %) lies within the southeast quadrant depicting
lower costs and improved health outcomes. Uncertainty
for the MRI and IL-6 test were greater than for the B cell
test and gene assay as shown by the width and height of
the cloud, which is a consequence of the low specificity of
0.60 (MRI) and 0.53 (IL-6).
Figure 3 shows the cost-effectiveness acceptability
curves for the add-on test strategy for intermediate-risk
patients. If a willingness-to-pay threshold of €20,000 per
QALY gained is used, there is a probability of cost-
effectiveness for the B-cell test of 100 %.
Univariate sensitivity analysis
The sensitivity of our results was evaluated by varying
single model parameters and comparing the ICERs to
the base-case ICERs of the most cost-effective test (B
cell) and the most effective test (MRI) when used as the
add-on in intermediate-risk patients. The base-case
ICERs were estimated using an improvement of 0.2 in
the DAS28 at 12 months in the FN patients, 10 % of FP
patients with biologic DMARD costs in the first year
after diagnosis and the test-specific sensitivity, specificity
and costs.
For a B-cell test, the change in specificity had the lar-
gest impact (see Fig. 4), followed by improvement in the
DAS28 in TP patients in the new test strategy, who were
FN in the current test strategy. No improvement in the
DAS28 resulted in an ICER of about €16,000, while an
improvement of 0.6 in the DAS28 resulted in a domin-
ant new test strategy (i.e., better health outcomes and
lower costs). Varying the new test costs, the number of
FP patients having biological DMARD costs between
0 % and 20 %, and sensitivity had less impact on the
ICER, but still caused variation.
For MRI, the change in improvement in the DAS28 in
TP patients in the new test strategy, who were FN in the
current test strategy, had the largest impact (see Fig. 4).
No improvement in DAS28 resulted in an ICER of about
€56,000, while an improvement of 0.6 in the DAS28
resulted in an ICER of about €3000. Changing sensitivity
to 0.50 or 1.00 had about the same impact as varying the
number between 0 % and 20 % of FP patients having
biological DMARD costs. Adjustments in specificity and
costs had the least impact on the ICER.
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Discussion
Various new medical technologies enable the detection of
RA at an increasingly earlier stage. RA is a disease in
which early detection has high potential because there
are treatments available that effectively reduce disease
progression, especially if introduced early in the disease.
In our study, we compared four different tests and we
found that a B-cell test was the most cost-effective test in
Table 1 Reclassification table with the results for intermediate-risk patients according to the ACR/EULAR 2010 RA classification
criteria and for all patients
Number of patients
according to
ACR/EULAR 2010
RA classification
criteria
Number of
patients reclassified
as high risk
Number of
patients reclassified
as low risk
Combined sensitivity:
RA-2010 criteria +
new test
Combined specificity:
RA-2010 criteria +
new test
(A) Add-on test for all patients
B cell test 0.85 0.69
High risk 243 243 0
Intermediate risk 263 75 (29 %) 188 (71 %)
Low risk 46 13 (28 %) 33 (72 %)
IL-6 test 0.89 0.41
High risk 243 243 0
Intermediate risk 263 146 (56 %) 117 (44 %)
Low risk 46 26 (57 %) 20 (43 %)
Magnetic resonance imaging 0.96 0.46
High risk 243 243 0
Intermediate risk 263 154 (59 %) 109 (41 %)
Low risk 46 26 (59 %) 20 (41 %)
Genetic assay test 0.77 0.66
High risk 243 243 0
Intermediate risk 263 64 (24 %) 199 (76 %)
Low risk 46 11 (24 %) 35 (76 %)
(B) Add-on test for intermediate-risk patients
B cell test 0.81 0.71
High-risk 243 243 0
Intermediate risk 263 75 (29 %) 188 (71 %)
Low risk 46 0 46
IL-6 test 0.85 0.46
High risk 243 243 0
Intermediate risk 263 146 (56 %) 117 (44 %)
Low risk 46 0 46
MRI 0.91 0.51
High risk 243 243 0
Intermediate risk 263 154 (59 %) 109 (41 %)
Low risk 46 0 46
Genetic assay test 0.75 0.67
High risk 243 243 0
Intermediate risk 263 64 (24 %) 199 (76 %)
Low risk 46 0 46
Combined sensitivity = sensitivity of American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 rheumatoid arthritis (RA)
classification criteria + sensitivity of the new test. Combined specificity = specificity of ACR/EULAR 2010 RA classification criteria + specificity of the new test.
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all test strategies. This is mainly due to the high specificity
(0.90) in combination with moderate sensitivity (0.60), and
relatively low test costs (€150). When the specificity of the
test increases, the number of FP patients who may receive
unnecessary expensive treatment is reduced, which largely
increases the likelihood that the test becomes cost-
effective. MRI was the second most cost-effective test as
an add-on in intermediate-risk patients. Mainly as a result
of the higher costs of MRI (€756) compared to a B-cell
test (€150), MRI was less cost-effective, even though it
had much higher sensitivity than the B-cell test (0.90
versus 0.60). However, the MRI had lower specificity,
which had more impact on the ICER than lower sensitiv-
ity. The specificity is more important because an add-on
Table 2 Five-year cost-effectiveness of new test strategies versus current test strategy
Test strategy New test Sea Spa Test costsa TP n (%) FP n (%) TN n (%) FN n (%) Costs QALYs ΔCosts ΔQALYs ICER Headroomb
ACR/EULAR
2010 RA
0.62 0.77 €1,593d 185 (34) 58 (11) 195 (35) 114 (21) €16,784 3.430
Add-on all
patients
B-cell 0.60 0.90 €150 254 (46) 77 (14) 175 (32) 46 (8) €16,807 3.454 €23 0.024 €969 €602
IL-6 0.70 0.53 €50 265 (48) 149 (27) 103 (19) 34 (6) €17,387 3.451 €603 0.021 €28,171 -€125e
MRI 0.90 0.60 €756 288 (52) 135 (24) 117 (21) 11 (2) €17,848 3.461 €1,063 0.031 €34,318 €312
Genetic 0.40 0.85 €750 231 (42) 87 (16) 166 (30) 69 (13) €17,611 3.444 €827 0.014 €57,606 €210
Add-on
intermediate-risk
patients
B-cell 0.60 0.90 €150 244 (44) 74 (13) 178 (32) 56 (10) €16,748 3.450 -€37 0.020 Dominantc €511
IL-6 0.70 0.53 €50 254 (46) 135 (24) 117 (21) 46 (8) €17,271 3.448 €487 0.018 €26,696 -€72e
MRI 0.90 0.60 €756 273 (49) 124 (22) 128 (23) 27 (5) €17,404 3.456 €620 0.026 €23,457 €269
Genetic 0.40 0.85 €750 224 (41) 82 (15) 170 (31) 75 (14) €17,211 3.442 €427 0.012 €35,233 €173
Example of what would happen if one would replace the RA classification criteria
Replacement all B-cell 0.60 0.90 €150 180 (33) 25 (5) 227 (41) 120 (22) €15,983 3.432 -€801 0.002 Dominantc €984
IL-6 0.70 0.53 €50 210 (38) 119 (22) 134 (24) 90 (16) €16,849 3.434 €64 0.004 €17,526 €59
MRI 0.90 0.60 €756 270 (49) 101 (18) 151 (27) 30 (5) €17,139 3.458 €355 0.027 €12,906 €951
Genetic 0.40 0.85 €750 120 (22) 38 (7) 214 (39) 180 (33) €16,675 3.414 € -110 -0.016 €6,914 €543
Se sensitivity, Sp specificity, TP true positive, FP false positive, TN true negative, FN false negative, QALY quality-adjusted life year, ICER incremental cost-effectiveness ratio
(€ per QALY gained), ACR/EULAR American College of Rheumatology/European League Against Rheumatism, RA rheumatoid arthritis, MRI magnetic resonance imaging.
aThese are the Se, Sp and costs of the new test; the Se and Sp of the combination of the new test plus the ACR/EULAR criteria are reported in the text. bWillingness to pay
threshold is €20,000 per QALY gained. cDominant = better health outcomes and lower costs. dCosts of visits and diagnostic tests during first year. eMainly due to the low
specificity, an IL-6 test as an add-on can never be cost-effective compared to the current test strategy
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test with a specificity below 100 % results in more patients
classified as FP, while these patients were TN according to
the current test strategy.
This study indicated where it is most likely to position
a new diagnostic test given the sensitivity, specificity and
costs in relation to the current RA-2010 criteria test
strategy. B-cell gene expression as an add-on test in
intermediate-risk patients was the most likely cost-effective
add-on strategy and could even replace the RA-2010 cri-
teria, given its moderate sensitivity (0.60), high specificity
(0.90) and low costs (€150). However, it is unlikely that a
replacement test would be discovered that provides the
rheumatologists with the same richness of information as
the current RA-2010 criteria. To use a new test in addition
to the RA-2010 criteria in all patients is the least cost-
effective, because it would not alter treatment for the high-
0
.2
.4
.6
.8
1
P
ro
ba
bi
lit
y 
co
st
−
ef
fe
ct
iv
e
0 20,000 40,000 60,000 80,000 100,000 120,000
QALY willingness−to−pay threshold (in Euros)
Comparator B−cell test IL−6 test
MRI Genetic assay
Fig. 3 Cost-effectiveness acceptability curves for add-on for the intermediate-risk test strategy and the current diagnostic test strategy. Current
test strategy = American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 rheumatoid arthritis (RA) classification
criteria. QALY quality-adjusted life year, MRI magnetic resonance imaging
Fig. 4 Impact of varying model inputs on incremental cost-effectiveness ratio for an add-on B-cell test or magnetic resonance imaging (MRI) in
intermediate-risk patients. QALY quality-adjusted life year, ICER incremental cost-effectiveness ratio, FP false positive
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risk patients (243 of 552 patients). These patients will have
higher test costs without additional health gain.
The discussion about the potential benefits of early
detection and treatment of RA is also relevant in the light
of the current discussion about biosimilar drugs. Cur-
rently, the price of biologic DMARDs is set at €14,000 per
patient per year. Due to this high price (which is about the
same for all biologic DMARDs), it is an important driver
of the cost-effectiveness results. If the price of a biosimilar
will be significantly lower, it will have a smaller impact on
the results. On the one hand, this could result in starting
biological drugs earlier, resulting in more TP patients
using biologic DMARDs. On the other hand, a cheaper
biosimilar may worsen the cost-effectiveness of new tests
because the savings from postponing or preventing treat-
ment with a biologic drug are smaller. The net result is
hard to predict, as prescription behaviour may change with
lower costs of biological drugs.
The results of our study are likely to be generalizable to
other countries and different healthcare systems because
the RA-2010 criteria are widely used internationally for
classifying RA. The costs of diagnostic tests and treatment
patterns obviously differ between countries and healthcare
systems (e.g., higher costs in the USA). However, this
would not result in differences in the most cost-effective
test strategy.
The results of our simulation should be interpreted
taking into account that we used fixed values for the
sensitivity, specificity and costs of the alternative tests.
This was done to show the differences in early cost-
effectiveness between tests with different test character-
istics. If we had added distributions around these
parameters, the differences in cost-effectiveness between
the tests would likely decrease due to large uncertainties
of these parameters in early-CEA. To overcome this, we
performed univariate sensitivity analysis to explore the
impact of changing these parameters. We found that
multiple factors had an impact on the cost-effectiveness
of a new test strategy. The main drivers of the ICER
include the sensitivity, specificity and costs of the new
test, but also the improvement in the DAS28 for TP
patients in the new test strategy, who were FN according
to the RA-2010 criteria, and the percentage of FP pa-
tients with biological DMARD costs in the first year
after diagnosis.
In addition, as RA is a heterogeneous disease, a new test
might provide additional diagnostic information in par-
ticular subgroups, such as obese patients or those with co-
existent osteoarthritis. Furthermore, the choice of a new
test might also be guided by additional diagnostic infor-
mation that is expected in particular subgroups. Further
research should investigate the impact of this additional
diagnostic information on the cost-effectiveness of these
new tests.
Like any early-CEA study, our study had limitations.
One was that limited data were available on long-term
disease progression in a cohort receiving usual care.
Therefore, we had to synthesize data from different data
sources and to make assumptions about the new test
strategies based on expert opinion. Typically, the im-
provement in health outcomes of adding a new test
without observed data is difficult to estimate. In the first
year after diagnosis, we assigned equal improvements in
utilities for TP and TN patients, less gain for FP pa-
tients, and reduced utilities for FP patients. Whether this
reflects clinical practice needs to be proven. Another
limitation could be that a death state was not included
in our model. However, because of the low (1–2 %) mor-
tality risk observed in patients with RA during 5 years of
follow up [49], and the equal mortality risk with the
current and new diagnostic test strategy, the mortality
risk would not influence the model results.
Conclusions
We have shown that the B-cell gene expression as an
add-on test for intermediate-risk patients was the most
likely cost-effective add-on strategy. A new add-on test
for intermediate-risk patients should have high specifi-
city and the costs should not be higher than €200–€300.
Endnotes
1Moderate and severe DAS28 were categorised in one
disease state. As treatment choice is based on DAS28 >3.2,
our categorisation does not affect the model results.
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